“We are pleased to welcome Jesse to the Axogen team," said Michael Dale, Chief Executive Officer, and Director, Axogen. "His extensive experience in regulatory strategy and deep understanding of the ...

while the follower axons in LRP4 mutants could not regenerate through the injury gap, resulting in poor regeneration (Gribble et al., 2018). LRP4 was widely recognized because it was involved in the ...

Schematic depicting the involvement of regional sympathetic nerves in the mediation of pain in early-stage TMJ-OA. GA, UNITED STATES, Febru ...

The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...

Via a collaboration with Nasa, Auxilium has installed a 3D printer on the ISS to test the promise of manufacturing in microgravity.

It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

On the cold morning of January 31, 2006, Nitin Narain, a 25-year-old Delhi native, began experiencing unusual fatigue, ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.